Jump to any asset
849 assets, updated daily
As of September 27, 2026, West Pharmaceutical Services Inc. (WST) trades at $370.44. CleaRank Financial AI rates it Buy with a fair value of $410.00, 10.7% above the current price. Wall Street's consensus target is $410.00 across 17 analysts. RSI at 74 is in overbought territory, and the price is above its 50-day average of $350.44.
West Pharmaceutical Services Inc. (WST)
West Pharmaceutical Services Inc. NYSE
$370.44
-3.160 (-0.85%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
76 / 100
West Pharmaceutical Services Inc. (WST) is currently trading at $370.44, above its 50-day and 200-day moving averages ($350.44 and $299.78), indicating positive short-to-medium term momentum. The stock's RSI is in overbought territory at 74.18, suggesting a potential for a short-term pullback, but the overall trend remains bullish. Analysts maintain a strong Buy consensus with a median price target of $410, implying an upside of 10.7% from current levels. The company's financial health is solid, with a healthy profit margin of 16.98% and a low debt-to-equity ratio of 0.11, comparing favorably to sector averages. Despite the overbought technicals, the fundamental outlook for WST remains positive, driven by consistent earnings beats and projected revenue growth. The company's ability to consistently exceed earnings estimates, as seen in its recent quarterly reports, confirms its operational strength. While the current price action suggests caution due to overbought conditions, the underlying business fundamentals and analyst sentiment support a continued upward trajectory over the medium to long term.
WST Price Analysis
Market Metrics
Open
$372.01
Day Range
$368.45 to $372.14
Prev Close
$373.60
Volume
434.0K
52-Week Range
$223.83 to $386.00
Market Cap
$26.07B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+47%), suggesting market expectations for superior growth or market position.
WST Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, WST beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
WST Analysis
Company's Health
4/5
12-Month Analyst Target
+10.68% Upside
Median of 17 analysts (12-month)
$410.00
AI Technical Analysis
West Pharmaceutical Services Inc. (WST) is trading above its 50-day and 200-day moving averages ($350.44 and $299.78), signaling an uptrend. The 50-day SMA is at $350.44 and the 200-day SMA is at $299.78, with the current price of $370.44 comfortably positioned above both. The Relative Strength Index (RSI) is currently at 74.18, indicating overbought conditions and a potential for a short-term correction. The Moving Average Convergence Divergence (MACD) is positive at 6.86, supporting the bullish momentum. Key support levels are identified around the 50-day SMA at $350.44 and the 200-day SMA at $299.78. Resistance is less clearly defined given the upward trend, but previous price action suggests psychological levels may emerge. Volume on the latest trading day was 434,000, which is below the average volume of 742,340, suggesting a slight decrease in trading activity as the stock approaches overbought territory. The overall chart structure indicates a strong bullish trend, but the overbought RSI warrants monitoring for potential consolidation or a minor pullback.
ProTips
- Monitor the RSI for WST, which is currently overbought at 74.18, for signs of a potential pullback or consolidation.
- Given the moderate insider selling signal, keep an eye on future insider transactions for any changes in sentiment.
- The company pays a dividend of $0.88 annually, yielding approximately 0.24% at the current price, which may appeal to income-focused investors.
Key Catalysts
Bullish
Consistent Earnings Beats
WST has a track record of exceeding analyst EPS estimates, demonstrating strong operational execution and financial discipline.
Source: Earnings ReportsBullish
Strong Return on Equity
The company's ROE of 19.09% significantly outperforms the sector average, indicating efficient capital utilization and profitability.
Source: Company FundamentalsBearish
Overbought Technical Conditions
The RSI is at 74.18, signaling that the stock may be overextended and due for a short-term correction or consolidation.
Source: Technical AnalysisBearish
Moderate Insider Selling
Insiders have sold $6.6 million worth of stock across 42 transactions, indicating a moderate sell signal that warrants attention.
Source: Insider TransactionsNeutral
Premium Valuation Multiples
WST trades at higher P/E and P/S ratios than its sector peers, suggesting that its current price may already reflect significant growth expectations.
Source: Fundamental AnalysisMarket Outlook
The base case scenario for West Pharmaceutical Services Inc. (WST) over the next 6-12 months anticipates continued growth, supported by analyst price targets averaging $405.375 and a median target of $410. The company's strong ROE of 19.09% and consistent earnings beats suggest it can maintain its premium valuation. Forward-looking revenue growth estimates for the current year are around 10.00%, with next year projected at 6.00%, indicating sustained business expansion. Potential upside catalysts include further market share gains in its specialized medical device segment and successful new product introductions. Conversely, downside risks involve the stock's current overbought technical condition (RSI 74.18) which could trigger a short-term correction, and the higher valuation multiples compared to sector averages. Any significant slowdown in revenue growth or unexpected competitive pressures could also impact the stock's performance.
Key Statistics
| Market Cap | 26.07B |
|---|---|
| P/E Ratio | 46.95 |
| EPS (TTM) | 7.89 |
| Dividend Yield | 0.24% |
| 52 Week High | 386.00 |
| 52 Week Low | 223.83 |
West Pharmaceutical Services Inc. (WST) exhibits strong fundamental characteristics with a current P/E ratio of 46.95, which is higher than the sector median of 31.9, suggesting a premium valuation. However, its Price-to-Sales ratio of 7.84 is also above the sector median of 3.7, reinforcing the premium. The company's Return on Equity (ROE) stands at a strong 19.09%, significantly outperforming the sector average of 6.9%. Its Net Profit Margin is healthy at 16.98%, and the Debt-to-Equity ratio is a low 0.11, indicating a strong balance sheet. Despite the higher valuation multiples, WST's superior profitability and efficient capital utilization justify some of this premium. The company's ability to generate strong returns on equity and maintain healthy profit margins, coupled with a conservative debt level, provides a solid foundation. While investors should be mindful of the current valuation, the underlying financial strength and operational efficiency suggest that the premium may be warranted by the company's performance and growth prospects.
Earnings & Growth Analysis
West Pharmaceutical Services Inc. (WST) demonstrated strong earnings performance in its most recent reported quarters. For the quarter ending June 2026, the company reported an EPS of $2.37, beating the estimate of $2.08 by 13.94%, although the stock experienced a price decline of -7.67% on the announcement. Prior quarters also showed consistent earnings beats, with the quarter ending March 2026 showing a 26.79% surprise and the quarter ending December 2025 a 11.48% surprise. This pattern of exceeding analyst expectations highlights the company's operational execution and ability to deliver on financial targets.
Key Risks
The primary risk for West Pharmaceutical Services Inc. (WST) is its current valuation, with a P/E ratio of 46.95 and a Price-to-Sales ratio of 7.84, both exceeding sector medians. The stock's RSI is in overbought territory at 74.18, indicating potential for a short-term pullback. Additionally, insider activity shows a moderate sell signal, with $6.6 million in net sales across 42 transactions, which warrants monitoring for any sustained trend.
Technical Indicators
| RSI (14) | 74.18 |
|---|---|
| MACD | 6.86 |
| SMA 50 | 350.44 |
| SMA 200 | 299.78 |
RSI
Overbought
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($350.44) above the 200-day SMA ($299.78), price action is firmly bullish above key moving averages, RSI at 74.2 indicates overbought conditions; consider caution for immediate entries.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.16
Weak correlation
Nasdaq 100 (QQQ)
+0.13
Weak correlation
Bitcoin (BTC)
+0.14
Weak correlation
Gold (XAU)
+0.01
Weak correlation
Check Custom Correlation
How does any other asset move with WST? One year of daily closes, Pearson correlation.
Try
WST Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$363.03
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$370.44
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$349.96
MAX LOSS
-3.6%
Volatility-Adjusted Stop Loss
Calculated based on RSI (74.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$381.18
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$399.33
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$417.49
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for WST is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in WST in September 2016 would be worth about $50,393 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in WST today could grow to about $30,883 by 2036 in the base case, with a bull case near $131,252 and a bear case around $7,267. Projections are statistical simulations, not guarantees.
WST Stock Price Prediction: 2030
CleaRank's simulation projects a price near $582 for WST by 2030 in the base case, from $370 today (1.6x over 4 years). The downside path ends near $233. These are outcomes of a Monte Carlo simulation run on WST's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $262 | $415 | $655 |
| 2028 | $243 | $464 | $887 |
| 2029 | $235 | $520 | $1,148 |
| 2030 | $233 | $582 | $1,452 |
| 2031 | $234 | $651 | $1,811 |
| 2032 | $238 | $729 | $2,235 |
| 2033 | $243 | $816 | $2,737 |
| 2034 | $250 | $913 | $3,331 |
| 2035 | $259 | $1,022 | $4,033 |
| 2036 | $269 | $1,144 | $4,862 |
Method: 10,000 simulated price paths using WST's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
WST Insider Trading Analysis
Bought
None
No open-market buys
Sold
$6.6M
4 Transactions
Insiders
18
Active Traders
Avg Transaction
$1.6M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 7, 2024 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 66.0K | $24.2M |
| Feb 27, 2024 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 64.1K | $23.1M |
| Aug 8, 2023 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 44.0K | $17.4M |
| May 9, 2023 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 44.0K | $16.0M |
| Mar 7, 2023 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 44.0K | $14.2M |
| Dec 5, 2022 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 44.0K | $10.5M |
| Aug 6, 2024 | GREEN ERIC MARK
Chief Executive Officer
|
Sell | 30.7K | $9.4M |
| Aug 11, 2023 | LAI QUINTIN J. PH.D.
Officer
|
Sell | 21.1K | $8.3M |
| Aug 2, 2023 | BIRKETT BERNARD JOHN
Officer
|
Sell | 22.3K | $8.3M |
| May 18, 2017 | FEDERICI WILLIAM J
Chief Financial Officer
|
Sell | 55.0K | $5.2M |
Page 1 of 1
Frequently Asked Questions
What is West Pharmaceutical Services Inc.'s stock price forecast for 2030?
Based on Monte Carlo simulations, West Pharmaceutical Services Inc.'s (WST) stock price is projected to reach a base case of $581.58 by 2030. The downside projection is $232.91, while the upside projection is $1452.22. These figures represent statistical simulation outcomes, not guaranteed price targets.
Is West Pharmaceutical Services Inc. stock a buy right now?
West Pharmaceutical Services Inc. (WST) is currently rated a Buy with a consensus score of 76. Analysts have a median price target of $410, suggesting a 10.7% upside from the current price of $370.44. The stock is trading above key moving averages, indicating positive momentum, though it is in overbought territory.
What are the key technical indicators for WST stock?
WST is trading above its 50-day and 200-day moving averages ($350.44 and $299.78), indicating an uptrend. The RSI is at 74.18, signaling overbought conditions, while the MACD is positive at 6.86, suggesting bullish momentum.
How does WST's valuation compare to its sector peers?
WST's P/E ratio of 46.95 and P/S ratio of 7.84 are higher than the sector medians of 31.9 and 3.7, respectively. However, its ROE of 19.09% significantly outperforms the sector average of 6.9%.
What was West Pharmaceutical Services Inc.'s recent earnings performance?
In the quarter to June 2026, WST reported an EPS of $2.37, exceeding estimates by 13.94%. The company has a history of consistent earnings beats, demonstrating strong operational execution.
Are insiders buying or selling West Pharmaceutical Services Inc. stock?
Insiders are net sellers of WST stock, with $6.6 million in total sales in recent filings and no reported purchases. This indicates a moderate sell signal, which investors should monitor.
What is the outlook for West Pharmaceutical Services Inc. over the next 6-12 months?
The outlook for WST is positive, with analysts projecting a median price target of $410. The company is expected to continue its growth trajectory, supported by strong fundamentals and consistent earnings performance, though near-term technical overbought conditions may lead to consolidation.